Pharma Pulse 10/29/24: Reassessing Pricing and Commercialization Approaches, Obesity Requires Pharmacotherapy, Not Just Lifestyle Interventions & more

Access Insights 2024: Reassessing Pricing and Commercialization Approaches

In a video interview with Pharma Commerce, Albert Thigpen, co-founder, Talentwise Consulting, discussed how the panel on “Playing the Chess Endgame–Healthcare Policies Targeting Drug Commercialization” underscored the complexities of implementing the Inflation Reduction Act (IRA), predicting significant challenges for stakeholders like retail pharmacies, payers, and pharmacy benefit managers. They highlighted concerns about the unintended consequences of negotiated maximum fair prices (MFPs), particularly on the generics industry and oncology drug distribution, which could complicate decisions for companies and affect in-office dispensing practices. Overall, the panelists noted that the IRA's intricate framework might lead to unforeseen difficulties in the healthcare landscape.

Some Disease Burden of Obesity Requires Pharmacotherapy, Not Just Lifestyle Interventions

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely known as treatments for type 2 diabetes, though some have been approved for indications beyond diabetes.

It’s Time to Ban Pharmaceutical Advertising

There are too many drug ads on social media to ever regulate them properly, and ads drive up prescription costs.

Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform

Parabilis Medicines™ (formerly FogPharma), announced a corporate name change. The company’s new name, Parabilis (pronounced puh-RAH-buh-liss), draws on Greek and Latin etymologies to mean both ‘beyond what’s possible’ and ‘obtainable,’ reflecting the company’s drive to expand what is therapeutically possible for the treatment of serious diseases, and its commitment to ensuring its medicines reach and benefit patients globally.

OM1, Inc. on LinkedIn

🧠 #MDMATherapy for #MentalHealthConditions: Do the Benefits Outweigh the Risks?

Carl D. Marci, M.D. sat down with Donald Tracy, MA at Pharmaceutical Executive to share what he thinks investigators can do to ensure these treatments are both safe and effective.

📍Read the full article here: https://hubs.ly/Q02VZJj80

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs